ZOETIS INC. ZTS

Zoetis Inc. es una empresa de salud animal. La compañía se enfoca en el descubrimiento, desarrollo, fabricación y comercialización de medicamentos, vacunas, productos y servicios de diagnóstico, biodevices, pruebas genéticas y tecnología de salud animal de precisión. Comercializa productos en ocho especies principales: perros, gatos y caballos, ganado, cerdos, aves de corral, peces y ovejas, y dentro de categorías de productos como vacunas, antiinfecciosos, parasiticidas, dermatología, otros productos farmacéuticos, aditivos alimenticios medicados y diagnósticos de salud animal. Opera a través de dos segmentos: Estados Unidos e Internacional. Dentro de cada uno de estos segmentos operativos, ofrece un portafolio de productos tanto para clientes de animales de compañía como de ganado, incluido Alfaxan. La empresa comercializa sus productos en aproximadamente 45 países en América del Norte, Europa, África, Asia, Australia y América del Sur, y sus productos se venden en más de 100 países.

Con 14 acciones de ZTS (USD 991,62) habrías recibido USD 29,26 en dividendos en los últimos 12 meses.

• GlobeNewswire Inc. 2 oct

  Vietnam Veterinary Vaccine Import Market and Top 10 Importers Guide 2023-2026 | Import Reliance and Aquaculture Growth Create Market Entry Opportunities

  Vietnam's veterinary vaccine import market is expanding due to growing livestock and aquaculture sectors, with imports valued at US$172 million in 2024. The market remains highly dependent on imported vaccines, particularly from the US (34.6%), China (12.8%), and Netherlands (8.7%). International companies like Zoetis, MSD Animal Health, and Boehringer Ingelheim maintain strong positions, while foreign investment opportunities are emerging through joint ventures and local manufacturing partnerships.

  

• Zacks Investment Research 1 oct

  Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why

  Zoetis (ZTS) ended trading at $69.10, down 1.05% from the previous day and 8.32% over the past month. The animal health company faces a negative earnings outlook with forecasted EPS down 10.59% and revenue down 3.66% for the upcoming quarter. The stock has been assigned a Zacks Rank of #5 (Strong Sell), though it trades at a discount to its industry average with a Forward P/E of 11.26.

  

• GlobeNewswire Inc. 28 sept

  Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1% - SNS Insider

  The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.

  

• Zacks Investment Research 18 sept

  Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note

  Zoetis stock declined 2.22% to $71.40, underperforming the broader market gains. The animal health company faces headwinds with projected EPS down 10.59% and revenue down 3.66% for the upcoming quarter. The company holds a Zacks Rank of #5 (Strong Sell) despite trading at a Forward P/E discount to its industry average.

  

• GlobeNewswire Inc. 7 sept

  Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030

  A comprehensive 249-page veterinary diagnostics market report covering 15 countries and 32 companies has been released, forecasting market trends through 2030. The report analyzes growth drivers including pet ownership patterns, agricultural modernization, and the One Health movement, while examining competitive positioning of major players like IDEXX, Zoetis, Antech, Roche, and Thermo Fisher across various diagnostic assay types, animal categories, and applications.